The healthiest cookies you’ll choose today

Our website uses cookies to collect useful information that lets us and our partners support basic functionality, analyze visitor traffic, deliver a better user experience, and provide ads tailored to your interests. Agreeing to the use of cookies is your choice. Learn more

Decline cookies Accept cookies
Skip to content
Fullscript leaf logo Sign in
Fullscript logo
Fullscript leaf logo
  • Our platform
    • Practitioner software
    • Pricing
    • Integrations
    • Patients on Fullscript
    • Book a demo
  • Learn
    • Spotlight
    • Protocols
    • Wellness blog
    • Practice resources
    • Webinars
    • Ingredient library
    • Practicing virtually
  • Support
    • Practitioner support
    • Patient help
    • Contact us
    • Or chat with us
Sign in Create account
Research Update
—

Research Update: A Randomized Controlled Trial on the Effect of Melissa Officinalis Syrup on Patients with Psoriasis

October 15, 2021
Fact checked
Written by Dr. Clara Sage Sartor, ND, BSc
Medically reviewed by
Dr. Natacha Montpellier, ND, B.Sc.
  1. Wellness blog
  2. Research Update: A Randomized Controlled Trial ...

Research Update articles are produced in order to keep practitioners up to date on impactful research that is relevant to the field of integrative medicine. These articles may contain summaries of recent studies, events, or other industry news that advance current knowledge and standards of care. The following article summarizes the research conducted by Yargholi et al. titled, “The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial,” which was published in the journal BMC Research Notes in 2021. (2)

Background

Psoriasis is a complex, immune-mediated inflammatory disease. (2) The development and pathology of this papulosquamous skin illness is derived from several immune factors including tumor necrosis factor alpha, dendritic cells, and T-cells. (1) Of those with psoriasis, 90% present with psoriasis vulgaris, also termed plaque psoriasis, which is a chronic disease involving plaque formations on the skin. (1) Psoriasis comprises varying levels of severity, is associated with increased risk of comorbidities, and does not always respond well to conventional therapies. Consequently, about 43 to 69% of patients seek out complementary and alternative medicine for treatment, primarily in the form of medicinal herbs. (2) This study aimed to investigate the efficacy of Melissa officinalis (M. officinalis), commonly referred to as lemon balm, in the form of a syrup prepared following traditional Persian medicine, as a treatment option for plaque psoriasis.

Effects of melissa officinalis syrup on patients with psoriasis

M. officinalis, commonly referred to as lemon balm, is an herb with many medicinal properties.

Methods

To meet the inclusion criteria, patients had to be at least 18 years of age with mild to moderate plaque psoriasis which was defined as having a score of less than 30% on the Psoriasis Area and Severity Index (PASI) as well as having less than 10% of body surface involvement. Participants also must not have participated in any other studies or phototherapy during the month preceding the trial. Patients with acute progressive psoriasis and tendency for erythroderma, other forms of psoriasis such as guttate, and a history of cardiovascular disease or cancer, as well as patients who were pregnant, lactating, or had allergies to components of the M. officinalis syrup were excluded from the study. Patients taking immunosuppressive drugs such as corticosteroids in the last four weeks or medications that may augment psoriasis symptoms such as beta-blockers were also excluded from the study.  The format of this study was a 12-week, randomized, double-blind, parallel-controlled trial. Participants were randomized into two groups, either intervention or control. The syrup consumed by the intervention group was prepared by adding 3 g of M. officinalis, 8 g of Rosa x damascena or Damask rose, and 1 g of Foeniculum vulgare or fennel to 450 ml of water and heated until the decoction reduced to 250 ml with the addition of honey as sweetener. The syrup consumed by the control group was prepared by adding sugar, caramel coloring additive, and 1% of rose water. Differences between the two syrups were undetectable regarding taste, odor, color, and viscosity.

Results

95 patients met the inclusion criteria and completed the trial with 47 in the intervention group and 48 in the control. Photographs of each participant’s skin were taken prior, during, and at the end of the trial. A sociodemographic questionnaire was used to collect data as well as the PASI ranging from 0-72, Dermatology Life Quality Index (DLQI) ranging from 0-30, and Visual Analogue Scale (VAS) ranging from 0-10 with the latter numbers representing higher severity of disease, higher impairment of quality of life, and higher severity of pruritus intensity, respectively. There were no determined differences between scale severity when comparing the groups at baseline; however, significant differences were noted as the trial continued. While no significant changes in DLQI score were observed, mean pruritus intensity score decreased from 6.34 ± 2.68 pre-intervention to 3.45 ± 2.18 at follow-up, whereas pruritus intensity score did not significantly decrease in the control group. The PASI score of the intervention group also significantly lowered compared to the control (1.65 ± 2.17 as compared to 3.36 ± 2.38). These results indicate that M. officinalis has potential to reduce PASI and pruritus severity in patients with mild to moderate plaque psoriasis.

Critical analysis

Overall, the study was well constructed with promising results indicating that not only was the medicinal syrup with M. officinalis able to reduce symptom severity but also that it appears to be safe, eliciting no known adverse effects during the trial. However, there were several limitations to the study. The long-term effects of the M. officinalis syrup could not be determined, as post-trial follow-up was not conducted. Furthermore, those with more severe forms of plaque psoriasis or non-plaque forms of psoriasis were omitted from the study; thus, information on how this treatment affects more severe forms of plaque psoriasis or non-plaque pathologies were not determined. The main form of data collection was from questionnaires, which were not assessed for bias. Moreover, while a VAS was also performed, no biochemical tests to analyze results of changes in the skin itself were performed due to financial constraints leading to a lack of objective data to support conclusions. Finally, while the study highlights the efficacy of M. officinalis, the efficacy and possible synergy of the other medicinal ingredients that were present in the experimental syrup though absent in the control were not addressed.

The bottom line

M. officinalis syrup may be a useful treatment option for those suffering from mild to moderate plaque psoriasis and provides a safe alternative compared to conventional forms of treatment. More research, ideally with biochemical testing included, is required to better assess its implication in more severe and diverse forms of psoriasis.

Fullscript simplifies supplement dispensing

Create your dispensary today I'm a patient
References
  1. Griffiths, C. E., & Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. Lancet (London, England), 370(9583), 263–271. https://doi.org/10.1016/S0140-6736(07)61128-3
  2. Yargholi, A., Shirbeigi, L., Rahimi, R., Mansouri, P., & Ayati, M. H. (2021). The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial. BMC research notes, 14(1), 253. https://doi.org/10.1186/s13104-021-05667-9

  • Print
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Pinterest

Disclaimer

The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Cancel reply

Your email address will not be published. Required fields are marked *

Prev Next
Back to main wellness blog page

Get more resources for your practice

Protocols
Practice resources
Ingredient library
Webinars

Share

  • Print
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • Pinterest

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.
Read more
Fullscript logo

We're certified carbon-neutral. It's part of our commitment to helping people get better.

American flag - toggles to show american specific contentUnited States
Canadian flag - toggles to show canada specific contentCanada
Product
  • Practitioner software
  • Integrations
  • Pricing
  • Patients
  • Supplement quality
  • Treatment adherence
  • Catalog
  • Wholesale
Company
  • Spotlight
  • About Fullscript
  • Collective
  • Leadership
  • Culture guide
  • Careers
  • Engineering
  • News
Support
  • Practitioner support
  • Patient help
  • Testimonials
  • General FAQ
  • Patient shipping
  • Wholesale shipping

© Fullscript 2023. All rights reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

  • Privacy Statement
  • Terms of Service
  • Accessibility Policy
  • Customer Support Policy
  • Acceptable Use Policy
  • California Privacy Notice
Send this to a friend